Is LCTX or LGND more undervalued in 2026?

CirclFi compares Lineage Cell Therapeutics, Inc. (LCTX) and Ligand Pharmaceuticals Incorpor (LGND) using 13 institutional-grade valuation models. LCTX has a Quality of Company score of 6.7/10 while LGND scores 7.8/10.

Which is a better buy — LCTX or LGND?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do LCTX and LGND valuations compare?

LCTX at $1.33 and LGND at $234.66 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

LCTX vs LGND Valuation Comparison 2026 — Intrinsic Value Analysis

LCTX

Biotechnology

Lineage Cell Therapeutics, Inc.

Quality

6.7

out of 10

Value Trap

SAFE

Price

$1.33

Last close

Models

9/13

Active

LGND

Biotechnology

Ligand Pharmaceuticals Incorpor

Quality

7.8

out of 10

Value Trap

LOW

Price

$234.66

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	LCTX Fair Value	LCTX Upside	LGND Fair Value	LGND Upside
Bayesian DCF	Intrinsic	$0.34	-74.5%	$66.47	-71.7%
Earnings Power Value	Intrinsic	—	—	$57.08	-75.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.23	-82.9%	$169.84	-27.6%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for LCTX vs LGND — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LCTX vs LGND — Which Stock Is More Undervalued?

LGND scores higher with a 7.8/10 quality rating vs LCTX's 6.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Lineage Cell Therapeutics, Inc. (LCTX) and Ligand Pharmaceuticals Incorpor (LGND) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LCTX currently trades at $1.33 with a QOC of 6.7/10, while LGND trades at $234.66 with a QOC of 7.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).